Grifols Biemat (GRFS) - מקדם חוב לטווח ארוך להון

The price action of Grifols, S.A. (GRFS) reflects a current level of 1.41. Grifols, S.A. (GRFS) ensures strict temperature control during the transportation of raw materials across its global supply chain. Business revenues are generated through the sale of albumin and immunoglobulins derived from donor plasma. Its status as a global leader and the complexity of its technical processes allow the issuer to maintain pricing power over its critical medications.

Outsourcing logistics and IT infrastructure allows Grifols, S.A. (GRFS) to optimize capital expenditures, which directly impacts the long-term debt-to-equity ratio. This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, determining the business's degree of leverage and its overall financial stability during periods of tight monetary policy.